胚胎植入前非整倍体遗传学筛查对改善男性因素不孕夫妇辅助生殖结局的研究进展

Role of preimplantation genetic testing for aneuploidies in male factor infertility

自胚胎植入前非整倍体遗传学筛查(preimplantation genetic testing for aneuploidies,PGT-A)技术开展以来,越来越多的不孕不育患者接受了这一治疗成功生育健康子代。PGT-A技术是通过遗传学手段对体外授精得到的胚胎进行染色体检测,从而达到筛选出染色体整倍体胚胎进行移植的目的。目前PGT-A主要用于女性高龄、反复流产或反复的胚胎种植失败。近年来,PGT-A也被推荐用于男性因素所致不孕不育的患者中。但PGT-A对男性因素不孕夫妇的辅助生殖治疗结局的改善作用,仍是学界探讨和研究的一个问题。本文综述了PGT-A与男性不育相关的研究进展,探讨PGT-A技术对男性因素不孕夫妇辅助生殖结局的改善作用。

Nowadays,more and more infertility couples have benefited from preimplantation genetic testing for aneuploidies(PGT-A).PGT-A is a technique that has used genetic technology to examine chromosomes in embryos from couples undergoing in vitro fertilization with the aim of helping select the normal chromosome embryo for transfer.PGT-A is mostly used for advanced maternal age,repeated miscarriage and repeated implantation failure.While for now male factor infertility,particularly severe oligoasthenozoospermia or severe teratozoospermia,is also regarded as one of the indications,it’s still controversial whether PGT-A could provide noteworthy aids for these patients.In this review,the effects of PGT-A on clinical outcomes of the patients who are involved in male factor infertilities are reviewed.